ArticleNature communications2026
Combined biosynthesis and site-specific incorporation of phenylalanine derivatives from aryl aldehydes or carboxylic acids.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined biosynthesis and site-specific incorporation of phenylalanine derivatives from aryl aldehydes or carboxylic acids.Nature communications · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Applications of genetic code expansion (GCE) in live cells are widespread and continually emerging, yet they have been limited by their reliance on the supplementation of non-standard amino acids (nsAAs) to cell culturing media. Here, we report the design of a single engineered bacterial host that performs the steps of phenylalanine derivative semi-synthesis and site-specific incorporation within target proteins. Our platform pathway exhibits broad substrate specificity towards commercially ubiquitous, achiral building blocks of aryl aldehydes or carboxylic acids, producing the family of nsAAs that are most frequently used for GCE. We demonstrate biosynthesis of 12 distinct nsAAs, and we observe combined biosynthesis and incorporation for these chemistries using common orthogonal translation systems (OTSs) based on a fluorescent reporter assay. We additionally show that the combination of nsAA biosynthesis and GCE steps can extend the chemical reach of the intrinsic biological containment strategy of synthetic auxotrophy from reliance on nsAAs to instead reliance on low-cost and achiral building blocks. Our platform should aid industrial-scale manufacturing of proteins that contain nsAAs and democratize access to expensive or commercially unavailable chemistries for labs that lack separations or traditional synthesis expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.